Harnessing Saccharomyces cerevisiae to Assess a Novel Genetic Circuit Targeting p53 & Mdm2 for Cancer Therapy
ISEF · 2025 Biomedical Engineering
Overview
The tumor suppressor protein p53, is mutated in 50% of human cancers. DNA damage activates kinases which stabilize p53 through phosphorylation and paradoxically can promote cancer cell survival when p53 is mutated. Current p53-targeting therapies aim to deliver wild-type p53 (wt-p53) or inhibit its negative regulator Mdm2. However, they face two main challenges: (1) directing p53's (variable) downstream effects towards apoptosis and (2) overcoming dominant-negative (dn-p53) variants that inhibit wt-p53 activity. To address these limitations, I designed a novel cancer therapeutic approach for targeted protein expression termed Genetic Circuit Therapy (GC-Therapy), and tested it in a p53-responsive Saccharomyces cerevisiae strain. The system independently expresses p53 fusion proteins containing a fluorescent reporter protein (EGFP) or pro-apoptotic proteins (hBAX or iCasp9), as well as Mdm2 under two independent promoters. I assessed p53 activity using an ADE2-based colorimetric colony assay, and EGFP activity using fluorescence measurements. p53 and EGFP activity was reduced by increasing Mdm2 expression and restored upon repressing Mdm2. Neither pro-apoptotic protein (hBAX/iCasp9) was able to significantly reduce cellular growth. Higher p53 expression outcompeted Mdm2 inhibition, suggesting a threshold effect. Fusions containing EGFP all expressed fluorescence, indicating proper folding and successful p53-tetramerization. However, Mdm2 did not fully abolish p53-EGFP fluorescence, likely due to immediate EGFP activity before degradation. This suggests that therapies should consider p53-fusion partners that have delayed rather than immediate effect so Mdm2 has time to degrade the protein. My findings offer preliminary insights into engineering similar genetic-circuits.
Competition history
- ISEF 2025
Resources
Related projects
ISEF · 2018
A Novel Approach to a p53-Stabilizing Agent to Accelerate Cell Apoptosis and Initiate Cell Arrest and Curb Malignancy of Tumor Cells
ISEF · 2019
p53-Bad: A Novel Mitochondrially Targeted Gene Therapy for Ovarian Cancer
ISEF · 2025
A Platform to Test the Therapeutic Impact of p53 Restoration
ISEF · 2014
An Investigation of the p53 Ubiquitin-Proteasome System Using a Novel Non-Steady-State Enzyme Kinetic Model
ISEF · 2015
Advancing the Cancer Stem Cell Approach for Early Tumorigenesis: Delineation of p53 Pathways in Differentially Expressed Tumor-Initiating Cells
ISEF · 2014
Characterization of Gene Expression in p53 Activated Tumor-Initiating Cells
ISEF · 2024
The Design of Spirooxindole-Pyrrolidinyl Scaffold as an Inhibitor of the MDM2 Protein
ISEF · 2021
Customized Cancer Cell Weapons: Using CRISPR dCas9 Genetic Engineering to modify MCF7 Human Breast Cancer Cells into Double Agent Treatment Vectors, Year III
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair